Authors

• Aislyn Boran
• Wallace Akerley
• Sergey Orlov (ORCID: https://orcid.org/0000-0002-3134-1989)
• Maximilian J. Hochmair (ORCID: https://orcid.org/0000-0002-8673-2450)
• Anna Robeva
• Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
• Sylvie Le Mouhaër
• Ji‐Youn Han (ORCID: https://orcid.org/0000-0001-5033-0006)
• Claudia Bossen (ORCID: https://orcid.org/0000-0002-1695-4744)
• Maja J.A. de Jonge (ORCID: https://orcid.org/0000-0002-1938-226X)
• Edward B. Garon (ORCID: https://orcid.org/0000-0001-7077-8801)
• Mariana Carbini
• Daniel S.W. Tan (ORCID: https://orcid.org/0000-0002-6514-6786)
• Rebecca S. Heist (ORCID: https://orcid.org/0000-0002-7397-2009)
• Harry J.M. Groen (ORCID: https://orcid.org/0000-0002-2978-5265)
• Takashi Seto (ORCID: https://orcid.org/0000-0002-2960-4364)
• Garrett M. Frampton (ORCID: https://orcid.org/0000-0002-2361-2750)
• Lauren Fairchild (ORCID: https://orcid.org/0000-0002-6135-5986)
• Makoto Nishio (ORCID: https://orcid.org/0000-0003-4969-4165)
• Noemı́ Reguart (ORCID: https://orcid.org/0000-0001-8190-499X)
• Yiqun Yang
• Johan Vansteenkiste
• A. Yovine
• Jürgen Wolf
• Pierre‐Jean Souquet
• Lexiang Ji

Institutions

• Novartis (Switzerland) (CH)
• University Medical Center Groningen (NL)
• University of California, Los Angeles (US)
• Leiden University Medical Center (NL)
• Boston Foundation (US)
• Massachusetts General Hospital (US)
• Novartis (China) (CN)
• Novartis (France) (FR)
• National Hospital Organization Kyushu Cancer Center (JP)
• Hospices Civils de Lyon (FR)
• Hôpital Lyon Sud (FR)
• National Cancer Center (KR)
• The Cancer Institute Hospital (JP)
• National Cancer Centre Singapore (SG)
• Erasmus MC Cancer Institute (NL)
• Karl Landsteiner Society (AT)
• Japanese Foundation For Cancer Research (JP)
• Foundation Medicine (United States)
• Saint Petersburg State Pediatric Medical University (RU)
• KU Leuven (BE)

Publication Details

Journal

The Lancet Oncology

Published

2024-09-30

DOI

https://doi.org/10.1016/s1470-2045(24)00441-8

Citations

54

Primary Topic

Lung Cancer Treatments and Mutations

Type

article

Field-Weighted Citation Impact

22.62

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Gilead Sciences
• Novartis Pharmaceuticals Corporation
• Regeneron Pharmaceuticals
• Taiho Pharmaceutical
• Novocure
• Agios Pharmaceuticals
• BeiGene
• Ono Pharmaceutical
• Ipsen
• Genentech
• EMD Serono
• Novartis Pharma
• Pfizer Japan
• Chugai Pharmaceutical
• Eli Lilly Japan
• Daiichi Sankyo Europe